A Quick Look at Today's Ratings for Cardinal Health(CAH.US), With a Forecast Between $124 to $139
Cardinal Health Is Maintained at Overweight by Barclays
Cardinal Health's Strong Pharmaceutical Growth and Strategic Moves Justify Buy Rating
Barclays Maintains Cardinal Health(CAH.US) With Buy Rating, Maintains Target Price $133
TD Cowen Maintains Cardinal Health(CAH.US) With Hold Rating, Raises Target Price to $130
UBS Maintains Cardinal Health(CAH.US) With Buy Rating, Raises Target Price to $134
Cardinal Health Is Maintained at Buy by UBS
Cardinal Health Analyst Ratings
Nephron Research Adjusts Price Target on Cardinal Health to $130 From $122
Evercore Maintains Cardinal Health(CAH.US) With Hold Rating, Maintains Target Price $125
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Cardinal Health (CAH) and Sanofi (OtherSNYNF)
Deutsche Bank Maintains Cardinal Health(CAH.US) With Hold Rating, Maintains Target Price $119
Baird Maintains Cardinal Health(CAH.US) With Buy Rating, Raises Target Price to $140
TD Cowen Maintains Cardinal Health(CAH.US) With Hold Rating, Maintains Target Price $116
Evercore Maintains Cardinal Health(CAH.US) With Hold Rating, Raises Target Price to $125
Barclays Maintains Cardinal Health(CAH.US) With Buy Rating, Maintains Target Price $117
Barclays Reaffirms Their Buy Rating on Cardinal Health (CAH)
Wells Fargo Maintains Cardinal Health(CAH.US) With Sell Rating, Maintains Target Price $101
Sell Rating on Cardinal Health Amid Acquisition Uncertainty and Competitive Concerns
Cardinal Health Analyst Ratings